Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

Blood (2016) 128 (22): 1209.

https://doi.org/10.1182/blood.V128.22.1209.1209

Published: 2016

Journal Articles

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

Thomas Köhnke, MD, Sandra Rechkemmer, Veit Leonhard Bücklein, MD, Kristina Pfannes, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2015) 126 (23): 2593.

https://doi.org/10.1182/blood.V126.23.2593.2593

Published: 2015

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

Journal Articles

ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL

Michaela Wagner, Madlen Oelsner, Peer-Hendrik Kuhn, MD, Torsten Haferlach, MD, Michael Fiegl, MD, Christian Bogner, MD, Christian Peschel, MD, Ingo Ringshausen, MD

Blood (2014) 124 (21): 1944.

https://doi.org/10.1182/blood.V124.21.1944.1944

Published: 2014

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Jan Boegeholz, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Stephanie Schneider, PhD, Klaus H. Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, Marion Subklewe, MD

Blood (2013) 122 (21): 239.

https://doi.org/10.1182/blood.V122.21.239.239

Published: 2013

Journal Articles

Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution

Maja Rothenberg-Thurley, Dr., Binje Vick, Dr., Stephanie Schneider, PhD, Bianka Ksienzyk, Philipp A Greif, MD, Michael Fiegl, MD, Marion Subklewe, MD, Wolfgang Hiddemann, M.D., Karsten Spiekermann, MD, Irmela Jeremias, MD, Klaus H. Metzeler, MD

Blood (2013) 122 (21): 49.

https://doi.org/10.1182/blood.V122.21.49.49

Published: 2013

Journal Articles

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Max Hubmann, MD, Marion Subklewe, MD, Thomas Köhnke, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Michael Fiegl, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, PhD

Blood (2012) 120 (21): 1404.

https://doi.org/10.1182/blood.V120.21.1404.1404

Published: 2012

Journal Articles

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Jan Braess, MD, PhD, Karsten Spiekermann, MD, PhD, Christian Buske, MD, PhD, Peter Staib, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Andreas Gruneisen, MD, Christa Sauerland, PhD, Michael Unterhalt, MD, PhD, Michael Fiegl, MD, Bernhard Wormann, MD, PhD, Wolfgang Kern, MD, PhD, Achim Heinicke, PhD, Wolfgang Berdel, MD, PhD, Thomas Büchner, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2007) 110 (11): 295.

https://doi.org/10.1182/blood.V110.11.295.295

Published: 2007

Journal Articles

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

Jan Braess, MD, PhD, Peter Staib, MD, PhD, Wolf D. Ludwig, MD, PhD, Bernhard J. Wormann, MD, PhD, Andreas Reichle, MD, PhD, Wolfgang Berdel, MD, PhD, Thomas Buchner, MD, PhD, Andreas Gruneisen, MD, Christoph Schmid, MD, Christian Schmid, MD, PhD, Wolfgang Kern, MD, PhD, Karsten Spiekermann, MD, PhD, Michael Fiegl, MD, Michaela Feuring-Buske, MD, PhD, Stefan Bohlander, MD, PhD, Achim Heinicke, Christ Sauerland, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 1997.

https://doi.org/10.1182/blood.V108.11.1997.1997

Published: 2006

Journal Articles

Treatment Intensity (TI) in Acute Myeloid Leukemia: A Novel Parameter for Ti-Assessment and Comparability.

Jan Braess, MD, PhD, Michael Fiegl, MD, Isolde Lorenz, MD, Inka Zimmermann, MD, Wolfgang Hiddemann, MD, PhD

Blood (2004) 104 (11): 1796.

https://doi.org/10.1182/blood.V104.11.1796.1796

Published: 2004

NARROW

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

Treatment Intensity (TI) in Acute Myeloid Leukemia: A Novel Parameter for Ti-Assessment and Comparability.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only